Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study

Schizophrenia is a chronic and debilitating disorder, the etiology of which remains unclear. Apoptosis is a programmed cell death mechanism that might be implicated in neuropsychiatric disorders, including schizophrenia. In this study, we aimed to compare the serum levels of apoptosis among deficit...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychiatric disease and treatment 2016-01, Vol.12, p.1261-1268
Main Authors: Beyazyüz, Murat, Küfeciler, Tarkan, Bulut, Leyla, Ünsal, Cüneyt, Albayrak, Yakup, Akyol, Esra Soydaş, Baykal, Saliha, Kuloglu, Murat, Hashimoto, Kenji
Format: Article
Language:English
Subjects:
Apoptosis
Brain-derived neurotrophic factor
Development and progression
Medical research
Mental disorders
Monoclonal antibodies
Nervous system diseases
Neurodegeneration
Original Research
Schizophrenia
Somatotropin
Studies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Schizophrenia is a chronic and debilitating disorder, the etiology of which remains unclear. Apoptosis is a programmed cell death mechanism that might be implicated in neuropsychiatric disorders, including schizophrenia. In this study, we aimed to compare the serum levels of apoptosis among deficit schizophrenia (DS) syndrome patients, nondeficit schizophrenia (NDS) patients, and healthy controls (HCs). After the inclusion and exclusion criteria were applied, 23 DS patients, 46 NDS patients, and 33 HCs were included in the study. The serum apoptosis levels were measured using a quantitative sandwich enzyme immunoassay with human monoclonal antibodies directed against DNA and histones. There was a significant difference among the three groups in terms of the levels of apoptosis (F 2,96=16.58; P
ISSN:1176-6328
1178-2021
1178-2021
DOI:10.2147/NDT.S106993